Orally Disintegrating Tablet Market Trends and Forecast
The future of the global orally disintegrating tablet market looks promising with opportunities in the CNS disease, gastrointestinal disease, and CVS disease markets. The global orally disintegrating tablet market is expected to grow with a CAGR of 11.7% from 2025 to 2031. The major drivers for this market are the rising demand from pediatric & geriatric populations, the growing preference for patient-friendly drug delivery systems, and the increasing availability of ODT formulations for chronic & central nervous system disorders.
• Lucintel forecasts that, within the type category, anti-psychotics drug is expected to witness higher growth over the forecast period.
• Within the application category, CVS disease is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Orally Disintegrating Tablet Market
The orally disintegrating tablet market is undergoing dramatic evolution with the accelerating demand for patient-friendly dosage forms. The notable emerging trends encompass improvements in taste masking technologies, the formulation of more complex and higher dose ODTs, the incorporation of smart technologies, the rising focus on pediatric and geriatric care formulations, and the growing uptake of ODTs for over the counter applications and nutraceuticals. These trends are broadening the scope of ODT applications and market opportunities.
• Developments in Taste Masking Technologies: A major challenge in the formulation of ODTs is masking the bitter or unpleasant taste of the active pharmaceutical ingredient. The latest developments in microencapsulation, coating technologies, and the incorporation of new excipients are paving the way for the development of ODTs with much better palatability. This improves patient compliance, especially among pediatric and geriatric patients, and broadens the scope of drugs that can be developed as ODTs.
• Creation of Complex and Higher-Dose ODTs: In the past, ODTs were restricted to lower dose drugs. But with advancements in formulation and manufacturing technologies, it is now possible to create ODTs with higher doses of active pharmaceutical ingredients and more complex drug combinations. This broadens the therapeutic uses of ODTs to manage more serious conditions needing higher doses or combinations of multiple drugs in one, easy-to-administer dosage form.
• Smart Technology Integration: The integration of smart technologies, like sensors or near field communication (NFC) tags, into ODT packaging or even tablets themselves is an upcoming trend. This can allow for features such as adherence tracking, dosage monitoring, and even customized drug release, providing improved patient management and data capture for healthcare professionals. Although still in its nascent stages, this trend has the potential to completely transform medication adherence.
• Increasing emphasis on Pediatric and Geriatric Products: ODTs are especially suitable for pediatric and geriatric patients who might experience difficulty in swallowing standard tablets or capsules. Increasing emphasis is placed on the creation of age-targeted ODT products with pleasing flavors, textures, and dosages specific to these patient groups. Such a trend caters to the special needs of these patient groups and enhances medication compliance and overall therapy outcomes.
• Growing Adoption in Over the Counter and Nutraceutical Markets: The ease of use and convenience of ODTs are fueling their growing adoption in the over the counter (OTC) medication and nutraceutical markets. Customers are looking for easy-to-use dosage forms for everyday ailments such as allergies, pain, and gastrointestinal issues, as well as for vitamins and supplements. This shift is broadening the market beyond prescription medications and addressing a wider consumer base looking for easy health and wellness solutions.
These new trends are all coming together to collectively redefine the orally disintegrating tablet market by overcoming challenges of formulation, increasing therapeutic usage, incorporating smart technologies for better patient management, targeting the specific needs of the pediatric and geriatric patient population, and extending their application in the OTC and nutraceutical markets. These developments are making ODTs a progressively versatile and patient-friendly drug delivery system.
Recent Development in the Orally Disintegrating Tablet Market
The orally disintegrating tablet market is a rapidly evolving area within the field of pharmaceutical formulation, with newer innovations centered on optimizing drug delivery, patient experience, and creating a wide variety of drugs in this easy-to-use dosage format. Advances in manufacturing, materials, and therapeutic uses are major driving forces behind these developments.
• Improvements in Manufacturing Methods: New manufacturing methods, including freeze-drying (lyophilization), direct compression with proprietary excipients, and tablet molding, are being optimized to manufacture ODTs with enhanced mechanical strength, quicker disintegration rates, and greater drug loading capacity. These improvements enable the formulation of more drugs as ODTs.
• Novel Excipients Development: New excipients for ODTs play a key role in the achievement of such desired attributes as rapid disintegration, good mouthfeel, and efficient taste masking. Improved quality and patient acceptability of ODTs are being promoted by recent developments in superdisintegrants, co-processed excipients, and taste-masking agents.
• Increased Drug Approvals in ODT Formulations: Regulatory agencies are increasingly considering the advantages of ODTs for certain populations of patients and have responded accordingly by increasing newly approved drugs delivered as ODTs. It is seen throughout several therapeutic segments, such as central nervous disorders, pain syndromes, and gastrointestinal illnesses, and supports the increasing embracement of the dosage form.
• Increased Emphasis on Taste Masking: Patient compliance, particularly among pediatric and geriatric patients, is highly dependent on the taste of oral drugs. Recent advances have centered on using advanced taste-masking technologies, including microencapsulation, ion exchange resins, and lipid-based barriers, to disguise effectively the bad taste of active pharmaceutical ingredients in ODTs without altering their quick disintegration properties.
• New Therapeutic Area Expansions: Utilization of ODT technology is spreading to new areas. In recent times, the development of ODTs for vaccines, biologics, and other emerging therapeutic entities has been reported. Such an expansion shows the flexibility of ODTs as a drug delivery form for a wider range of pharmaceutical entities.
These new advances in manufacturing processes, excipient science, drug approvals, taste masking, and therapeutic uses are all collectively influencing the orally disintegrating tablet market by allowing for the development of more effective, tasty, and convenient drugs. These advances are fueling the growth and use of ODTs in many patient populations and therapeutic categories.
Strategic Growth Opportunities in the Orally Disintegrating Tablet Market
Strategic opportunities for growth in the orally disintegrating tablet market are focused on taking advantage of the distinctive strengths of this dosage form to meet particular patient requirements and market needs in various therapeutic and consumer health uses. These opportunities include targeting patient groups with dysphagia, improving compliance for chronic diseases, offering convenient self-treatment alternatives, and providing taste-masked formulations for pediatric use.
• Pediatric Formulations: ODTs have a major benefit in pediatric medicine because they are so easy to take without water and can be flavored with palatable tastes. Opportunities for strategic growth include creating ODT formulations for more pediatric drugs, such as antibiotics, antipyretics, and chronic childhood disease treatments, to improve compliance and enhance treatment outcomes in this difficult patient population.
• Geriatric Formulations: The geriatric population suffers from polypharmacy and dysphagia, for which ODTs are an appropriate dosage form. There are opportunities for growth in the development of ODTs for drugs that are frequently utilized in the elderly, including drugs for cardiovascular conditions, pain management, and neurodegenerative diseases. Handle-and-swallow-friendly formulations can improve significantly patientsÄX%$%X medication compliance and quality of life within this population.
• Central Nervous System (CNS) Disorders: Patients with CNS disorders like schizophrenia, epilepsy, and ParkinsonÄX%$%Xs disease often require long term medication and may have difficulty swallowing or are noncompliant. ODTs provide a convenient and subtle means of delivering these drugs, even without water. Opportunities for growth strategy include the development and marketing of ODT presentations for more CNS drugs with enhanced palatability and fast uptake.
• Over The Counter (OTC) Drugs: ODTsÄX%$%X ease of administration and convenience render them an ideal choice for OTC drugs. Expansion opportunities can be found in making ODTs more widely available for minor conditions like allergies, pain management, and stomach upsets. The convenience of taking these drugs on-the-go without water will appeal to time-strapped consumers and can stimulate market growth in the self-medication market.
• Dietary Supplements and Nutraceuticals: The dietary supplements and nutraceuticals market is shifting more and more towards convenient and palatable forms of dosing. ODTs provide a convenient alternative to the conventional tablet and capsule. Opportunities for strategic growth lie in developing more vitamins, minerals, and herbal supplements as ODTs to meet consumersÄX%$%X demands for convenient means of integrating these products into their lifestyle.
The orally disintegrating tablet market has strong strategic growth prospects in pediatrics, geriatrics, CNS disorders, OTC drugs, and nutraceuticals. By taking advantage of the benefits of ODTs in ease of use, palatability, and convenience, pharmaceutical and nutraceutical firms can target specific patient requirements and access growing market segments.
Orally Disintegrating Tablet Market Driver and Challenges
The growth and development of the orally disintegrating tablet market are influenced by several technological advancements in drug delivery, economic conditions affecting manufacturing and pricing, and the regulatory environment that oversees pharmaceutical products. Awareness of these drivers and challenges is important for market players to navigate the market and for patients to enjoy the convenience of this dosage form.
The factors responsible for driving the orally disintegrating tablet market include:
1. Patient Convenience and Compliance: The major impetus for the ODT market is increased patient convenience and better medication compliance, especially in patients with difficulty in swallowing (dysphagia), i.e., pediatric and geriatric patients. Its ease of ingestion without water and quicker disintegration render ODTs a preferred option, resulting in increased treatment adherence and efficacy.
2. Quick Drug Dissolution and Absorption: ODTs are formulated to break down rapidly in the oral cavity, resulting in quicker drug dissolution and possibly faster absorption than regular tablets. Such quick action is especially useful for drugs employed in the management of acute diseases such as pain or migraines, and this explains their use in the respective therapeutic applications.
3. Use with Water-Restricted Patients: For those patients with fluid restriction needs as part of their conditions, including those with renal dysfunction or congestive heart failure, ODTs provide an excellent alternative to traditional oral therapy needing water to swallow. Such is the significant role of ODTs in selected patient groups with special medical needs.
4. User-Friendly Formulations Demand in the Market: There is an increasing demand among patients and healthcare professionals for convenient and user-friendly drug formulations. ODTs satisfy this need by providing an easy and unobtrusive method of taking medication, leading to their rising popularity and market growth in a range of therapeutic classes.
5. Technological innovations in formulation: Continuous advancements in formulation technologies, including taste masking, stabilization of active ingredients, and achieving desired disintegration times, are expanding the range of drugs that can be successfully formulated as ODTs. These technological advances are one of the major drivers in the marketÄX%$%Xs capability to provide more advanced and efficient ODT products.
Challenges in the orally disintegrating tablet market are:
1. Bitter Drug Taste Masking: Most active pharmaceutical ingredients possess a bitter or unpalatable taste, which is a major hurdle in developing acceptable ODTs. Efficient taste-masking technologies may be intricate and expensive to use without compromising the fast disintegration characteristics of the tablet.
2. Fragility and Handling Problems: ODTs tend to be more fragile than traditional tablets because of their quick disintegration characteristics. This may cause problems in manufacturing, packaging, and handling, which can result in breakage or damage during the supply chain and by patients.
3. Increased Cost of Manufacturing: The excipients and specialized technologies involved in the preparation of ODTs tend to increase manufacturing cost relative to regular tablets. This can influence prices and affordability of ODTs, especially for price-conscious markets.
The orally disintegrating tablet market is fueled by the huge benefits the product provides in terms of patient convenience, fast action of the drug, appropriateness for certain patient groups, and general ease of use, with technological innovation in formulation. Taste masking, tablet breakage, and increased production cost are problems that must be overcome if the market is to grow further and make ODTs more accessible to the world.
List of Orally Disintegrating Tablet Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies orally disintegrating tablet companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the orally disintegrating tablet companies profiled in this report include-
• Teva
• Merck
• Viatris
• Pfizer
• Johnson and Johnson
• GSK
• Otsuka
• Eli Lilly and Company
• AstraZeneca
• Bristol-Myers Squibb
Orally Disintegrating Tablet Market by Segment
The study includes a forecast for the global orally disintegrating tablet market by type, application, and region.
Orally Disintegrating Tablet Market by Type [Value from 2019 to 2031]:
• Anti-Psychotics Drug
• Anti-Epileptics Drug
• Others
Orally Disintegrating Tablet Market by Application [Value from 2019 to 2031]:
• CNS Diseases
• Gastrointestinal Diseases
• CVS Diseases
• Others
Orally Disintegrating Tablet Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Orally Disintegrating Tablet Market
Current trends in the orally disintegrating tablet market in the United States, China, Germany, India, and Japan indicate an increasing trend towards patient-friendly drug delivery systems. ODTs have benefits such as convenience of administration without water, quick dissolution, and enhanced bioavailability for some drugs, which make them especially useful for pediatric, geriatric, and dysphagic patients. Advances in formulation and processing technology, combined with growing demand for user-friendly dosage forms, are fueling innovation and market growth in these target markets. Encouragement from regulatory bodies for patient-friendly products and the creation of new candidates that can be developed using ODT technology are also driving recent trends.
• United States: The US ODT market is established and continues to experience innovation in formulation technologies that are designed to enhance taste masking and disintegration times. Some of the latest developments include the introduction of new ODT formulations for a number of central nervous system disorders as well as pain management. Additionally, there is increased interest in creating over the counter ODT solutions for allergies and everyday ailments, with an emphasis on patient convenience and ease of access.
• China: The ODT market in China is growing at a fast pace due to an aging population and growing awareness of patient compliance. Recent trends involve the creation and approval of generic ODT formulations of popular drugs, making them more accessible. Local pharmaceutical firms are also making investments in research and development for the design of new ODT formulations with enhanced palatability and stability, reflecting local patient preferences.
• Germany: Germany is an important market for ODTs in Europe, with high demand for premium pharmaceutical products. Recent trends include the launch of innovative ODT formulations for neurological diseases and mental health disorders, frequently with advanced taste masking technologies. The market is also driven by strict regulatory requirements and emphasis on patient safety and efficacy.
• India: The Indian ODT market is dominated by increasing demand for low-cost and easy-to-consume forms. Recent trends have been the production of low-cost ODT forms of several therapeutic drugs, especially in pediatric and geriatric markets. Development of ODTs for nutraceuticals and dietary supplements is also gaining traction, signifying a larger trend towards convenient wellness and health products.
• Japan: Japan has an established ODT market, fueled by its sizeable aging population and high priority on patient comfort and use convenience. Recent trends include the launch of ODT products with better sensory profile, including enhanced mouthfeel and taste. Pharmaceutical firms are also highlighting the development of ODTs for drugs with a narrow therapeutic range, taking advantage of the fast dissolution to provide sure absorption.
Features of the Global Orally Disintegrating Tablet Market
Market Size Estimates: Orally disintegrating tablet market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Orally disintegrating tablet market size by type, application, and region in terms of value ($B).
Regional Analysis: Orally disintegrating tablet market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the orally disintegrating tablet market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the orally disintegrating tablet market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for orally disintegrating tablet market?
Answer: The global orally disintegrating tablet market is expected to grow with a CAGR of 11.7% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the orally disintegrating tablet market?
Answer: The major drivers for this market are the rising demand from pediatric & geriatric populations, the growing preference for patient-friendly drug delivery systems, and the increasing availability of ODT formulations for chronic & central nervous system disorders.
Q3. What are the major segments for orally disintegrating tablet market?
Answer: The future of the orally disintegrating tablet market looks promising with opportunities in the CNS disease, gastrointestinal disease, and CVS disease markets.
Q4. Who are the key orally disintegrating tablet market companies?
Answer: Some of the key orally disintegrating tablet companies are as follows:
• Teva
• Merck
• Viatris
• Pfizer
• Johnson and Johnson
• GSK
• Otsuka
• Eli Lilly and Company
• AstraZeneca
• Bristol-Myers Squibb
Q5. Which orally disintegrating tablet market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, anti-psychotics drug is expected to witness higher growth over the forecast period.
Q6. In orally disintegrating tablet market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, North America is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the orally disintegrating tablet market by type (anti-psychotics drug, anti-epileptics drug, and others), application (CNS diseases, gastrointestinal diseases, CVS diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Orally Disintegrating Tablet Market, Orally Disintegrating Tablet Market Size, Orally Disintegrating Tablet Market Growth, Orally Disintegrating Tablet Market Analysis, Orally Disintegrating Tablet Market Report, Orally Disintegrating Tablet Market Share, Orally Disintegrating Tablet Market Trends, Orally Disintegrating Tablet Market Forecast, Orally Disintegrating Tablet Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.